Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy

Vaccines
Giorgio ParmianiMichele Maio

Abstract

Antibodies to immune checkpoints have entered the clinical arena and have been shown to provide a clinical benefit for metastatic melanoma and, possibly, for other tumors as well. In this review paper we summarize this therapeutic activity and underline the functional mechanisms that may be involved. Among them, we discuss the so far neglected role of tumor-associated antigens (TAAs) deriving from tumor somatic mutations and summarize the results of recent trials showing the immunogenic strength of such TAAs which can be specifically targeted by T cells activated by immune checkpoint antibodies. Finally we discuss new immunotherapy approaches that involve the combination of self/shared- or neo-TAAs-based vaccines and immune checkpoint blockade antibodies, to increase the clinical response of metastatic melanoma patients.

References

May 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·P K SrivastavaL J Old
Sep 9, 2006·Science·Tobias SjöblomVictor E Velculescu
Feb 6, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Giorgio ParmianiChiara Castelli
Mar 17, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·R Houston ThompsonEugene D Kwon
Jun 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paola FilipazziLicia Rivoltini
Feb 5, 2008·Cancer Research·Neil H SegalJames P Allison
Feb 22, 2008·Proceedings of the National Academy of Sciences of the United States of America·F Stephen HodiGlenn Dranoff
Jan 28, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tiziano Di TomasoCristina Maccalli
Feb 18, 2010·Proceedings of the National Academy of Sciences of the United States of America·Michael A CurranJames P Allison
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Nov 9, 2010·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Sameena KhanEyad Elkord
Nov 26, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amod A SarnaikJeffrey S Weber
Jan 13, 2012·Cancer Research·John C CastleUgur Sahin
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Aug 11, 2012·Cancer Immunology, Immunotherapy : CII·Saskia J A M SantegoetsTanja D de Gruijl
Jan 10, 2013·Current Opinion in Oncology·Michele MaioAlexander M M Eggermont
Aug 16, 2013·Nature·Ludmil B AlexandrovMichael R Stratton
Sep 24, 2013·Lancet·Alexander M M EggermontCaroline Robert
Oct 16, 2013·Expert Review of Vaccines·Giorgio ParmianiCristina Maccalli
Oct 23, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey S WeberY Ann Chen
Nov 28, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Andrea VolontéCristina Maccalli
Dec 18, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Cristina MaccalliGiorgio Parmiani
Feb 4, 2014·Current Opinion in Immunology·Jose Luis Perez-GraciaIgnacio Melero
Feb 12, 2014·Cancer Immunology, Immunotherapy : CII·Caroline JochemsJeffrey Schlom
May 30, 2014·Science Translational Medicine·Edward ChaLawrence Fong
Jul 9, 2014·Nature Reviews. Clinical Oncology·Ignacio MeleroHåkan Mellstedt
Aug 2, 2014·Oncoimmunology·Marit M van BuurenTon Nm Schumacher
Aug 12, 2014·Cancer Immunology, Immunotherapy : CII·Cristina Maccalli, Ruggero De Maria
Aug 29, 2014·Cancer Immunology, Immunotherapy : CII·Zlatko TrajanoskiPaolo Dellabona
Sep 24, 2014·The Journal of Experimental Medicine·Fei DuanPramod K Srivastava
Nov 20, 2014·The New England Journal of Medicine·Alexandra SnyderTimothy A Chan
Nov 28, 2014·Nature·Matthew M GubinRobert D Schreiber
Dec 17, 2014·Expert Opinion on Investigational Drugs·Anasuya Gunturi, David F McDermott
Feb 3, 2015·Frontiers in Oncology·Margaret K CallahanJedd D Wolchok
Apr 22, 2015·The New England Journal of Medicine·Caroline RobertUNKNOWN KEYNOTE-006 investigators

❮ Previous
Next ❯

Citations

Mar 16, 2016·Cancers·Giorgio Parmiani
May 6, 2016·Frontiers in Immunology·Nicholas A Cacalano
Sep 27, 2016·Expert Review of Anticancer Therapy·Bibhusal ThapaTom John
Oct 25, 2017·International Journal of Molecular Sciences·Jessica RoelandsWouter Hendrickx
Jun 8, 2018·Expert Opinion on Biological Therapy·Lorenzo PillaCristina Maccalli
Sep 28, 2018·Seminars in Cancer Biology·Cristina MaccalliSoldano Ferrone

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Ron D JachimowiczAchim Rothe
Current Oncology Reports
Brenda Ernst, Karen S Anderson
Seminars in Oncology
Luana Calabrò, Michele Maio
© 2021 Meta ULC. All rights reserved